Teplizumab Dosing and Administration Protocol
Administer teplizumab as a 14-day consecutive daily intravenous infusion course using body surface area-based dosing, with mandatory premedication for the first 5 days, and if doses are missed, resume on consecutive days to complete all 14 doses. 1
Patient Selection Criteria
Before initiating teplizumab, confirm the patient meets all diagnostic criteria for Stage 2 type 1 diabetes 1:
- Age ≥8 years
- At least 2 positive pancreatic islet autoantibodies (GAD65, IAA, IA-2A, ZnT8A, or ICA)
- Dysglycemia without overt hyperglycemia documented by oral glucose tolerance test
- Clinical history excludes type 2 diabetes
Pre-Treatment Laboratory Requirements and Exclusions
Do not initiate teplizumab if any of the following are present 1:
- Lymphocyte count <1,000 cells/mcL
- Hemoglobin <10 g/dL
- Platelet count <150,000/mcL
- Absolute neutrophil count <1,500/mcL
- ALT or AST >2× upper limit of normal
- Bilirubin >1.5× upper limit of normal
- Laboratory or clinical evidence of acute EBV or CMV infection
- Active serious infection or chronic active infection (excluding localized skin infections)
Vaccination Requirements
Complete all age-appropriate vaccinations before starting teplizumab 1:
- Live-attenuated vaccines: Administer ≥8 weeks before treatment
- Inactivated or mRNA vaccines: Administer ≥2 weeks before treatment
Premedication Protocol
Mandatory premedication for Days 1-5 1:
- NSAID or acetaminophen
- Antihistamine
- Antiemetic (as needed)
Additional premedication doses may be administered if symptoms develop during infusion.
Dosing Schedule
Administer once daily by IV infusion over minimum 30 minutes 1:
- Day 1: 65 mcg/m²
- Day 2: 125 mcg/m²
- Day 3: 250 mcg/m²
- Day 4: 500 mcg/m²
- Days 5-14: 1,030 mcg/m²
Missed Dose Management
If a planned infusion is missed: Resume dosing by administering all remaining doses on consecutive days to complete the full 14-day treatment course. Do not administer two doses on the same day. 1
This is a critical practical detail—the treatment course must include all 14 doses, but they must be given consecutively once resumed, not on the originally planned schedule.
Preparation and Administration
Dilution requirements 1:
- Must dilute before use in either:
- Sterile glass vial with 18 mL of 0.9% Sodium Chloride, OR
- PVC infusion bag with 18 mL of 0.9% Sodium Chloride
- Each vial is single-dose only
- Inspect visually—solution should be clear and colorless
- Do not use if particulate matter or discoloration present
Storage of diluted solution 1:
- Store at room temperature (15-30°C/59-86°F)
- Complete infusion within 4 hours of preparation start
- Discard if not administered within 4 hours
Monitoring During Treatment
Key safety monitoring based on the most common adverse reactions 2, 1:
- Cytokine Release Syndrome (CRS): Monitor for fever, fatigue, muscle/joint pain, nausea, headache during first 5 days—these occur in the majority of patients
- Lymphopenia: Occurs in 73% of patients, usually transient 2
- Rash: Occurs in 36% of patients 2
- Liver enzymes: Monitor for elevation
Clinical Context and Evidence
The 2025 ADA Standards of Care recommend discussing teplizumab with selected patients ≥8 years with Stage 2 type 1 diabetes, emphasizing treatment must occur in settings with appropriately trained personnel 2. The pivotal trial demonstrated a median delay of 24 months in progression to Stage 3 diabetes (50 months vs 25 months, HR 0.41) 2.
Important predictors of response include presence of HLA-DR4, absence of HLA-DR3, and absence of anti-ZnT8 antibody, though the drug is not restricted to these subgroups 2.
Critical Practice Considerations
- Setting requirement: Must administer in facility with appropriately trained personnel capable of managing CRS and hypersensitivity reactions 2, 1
- Single treatment course: Current evidence supports one 14-day course; no data on repeat dosing
- Real-world data: Recent observational studies confirm glycemic improvements (2-hour OGTT glucose and HbA1c) within 2-6 months post-treatment 3
- No concurrent immunizations: Avoid live, inactivated, and mRNA vaccines during treatment 1
The premedication requirement for only the first 5 days reflects the timing of peak CRS risk, while the dose escalation strategy (Days 1-4) is designed to minimize initial cytokine release.